Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The entry "novel transcript, antisense to PATJ" (ENSG00000298960) does not correspond to a well-characterized protein, receptor, enzyme, or any established therapeutic target. It appears to represent a computationally annotated transcript that is antisense to the well-known **PATJ** gene (Protein Associated to Tight Junctions), but there is no evidence in current databases or scientific literature that this antisense transcript encodes a protein, possesses a defined biological function, or is considered a therapeutic target[1][3][5]. There are no widely recognized aliases, standardized names, or therapeutic roles associated with this entity. The canonical PATJ gene itself is distinct, encodes a scaffolding protein involved in tight junctions and epithelial polarity, and carries clinical relevance, but this antisense transcript is not itself a validated or characterized molecular target[1][3][4][5]. If you seek structured data for the **canonical PATJ gene** or its protein product, refer to "PATJ Crumbs Cell Polarity Complex Component" (PATJ, ENSG00000132849), which is a distinct and well-annotated entity[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to PATJ (ENSG00000298960).